vs
Side-by-side financial comparison of Cardiff Oncology, Inc. (CRDF) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
SenesTech, Inc. is the larger business by last-quarter revenue ($421.0K vs $243.0K, roughly 1.7× Cardiff Oncology, Inc.). SenesTech, Inc. runs the higher net margin — -428.5% vs -2969.5%, a 2541.0% gap on every dollar of revenue. On growth, Cardiff Oncology, Inc. posted the faster year-over-year revenue change (62.0% vs -16.0%). Over the past eight quarters, Cardiff Oncology, Inc.'s revenue compounded faster (8.9% CAGR vs 0.7%).
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
CRDF vs SNES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $243.0K | $421.0K |
| Net Profit | $-7.2M | $-1.8M |
| Gross Margin | — | 55.3% |
| Operating Margin | -3221.0% | -446.8% |
| Net Margin | -2969.5% | -428.5% |
| Revenue YoY | 62.0% | -16.0% |
| Net Profit YoY | 38.8% | -43.7% |
| EPS (diluted) | $-0.11 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $243.0K | $421.0K | ||
| Q3 25 | $120.0K | $690.0K | ||
| Q2 25 | $121.0K | $625.0K | ||
| Q1 25 | $109.0K | $485.0K | ||
| Q4 24 | $150.0K | $501.0K | ||
| Q3 24 | $165.0K | $482.0K | ||
| Q2 24 | $163.0K | $459.0K | ||
| Q1 24 | $205.0K | $415.0K |
| Q4 25 | $-7.2M | $-1.8M | ||
| Q3 25 | $-11.3M | $-1.3M | ||
| Q2 25 | $-13.9M | $-1.6M | ||
| Q1 25 | $-13.4M | $-1.7M | ||
| Q4 24 | $-11.8M | $-1.3M | ||
| Q3 24 | $-11.9M | $-1.5M | ||
| Q2 24 | $-11.8M | $-1.6M | ||
| Q1 24 | $-10.0M | $-1.8M |
| Q4 25 | — | 55.3% | ||
| Q3 25 | — | 62.8% | ||
| Q2 25 | — | 65.4% | ||
| Q1 25 | — | 64.5% | ||
| Q4 24 | — | 60.9% | ||
| Q3 24 | — | 65.4% | ||
| Q2 24 | — | 54.2% | ||
| Q1 24 | — | 32.5% |
| Q4 25 | -3221.0% | -446.8% | ||
| Q3 25 | -9978.3% | -195.2% | ||
| Q2 25 | -12212.4% | -258.2% | ||
| Q1 25 | -13194.5% | -342.9% | ||
| Q4 24 | -8381.3% | -250.9% | ||
| Q3 24 | -7637.0% | -321.0% | ||
| Q2 24 | -7696.3% | -349.0% | ||
| Q1 24 | -5333.2% | -444.1% |
| Q4 25 | -2969.5% | -428.5% | ||
| Q3 25 | -9381.7% | -188.1% | ||
| Q2 25 | -11523.1% | -258.6% | ||
| Q1 25 | -12324.8% | -343.3% | ||
| Q4 24 | -7858.0% | -250.5% | ||
| Q3 24 | -7184.8% | -313.9% | ||
| Q2 24 | -7225.8% | -345.1% | ||
| Q1 24 | -4883.4% | -441.4% |
| Q4 25 | $-0.11 | $0.48 | ||
| Q3 25 | $-0.17 | $-0.28 | ||
| Q2 25 | $-0.21 | $-0.87 | ||
| Q1 25 | $-0.20 | $-1.28 | ||
| Q4 24 | $-0.22 | $-0.15 | ||
| Q3 24 | $-0.25 | $-2.07 | ||
| Q2 24 | $-0.26 | $-3.08 | ||
| Q1 24 | $-0.22 | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.3M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.4M | $9.6M |
| Total Assets | $61.9M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.3M | $8.6M | ||
| Q3 25 | $60.6M | $10.2M | ||
| Q2 25 | $71.0M | $6.1M | ||
| Q1 25 | $79.9M | $1.7M | ||
| Q4 24 | $91.7M | $1.3M | ||
| Q3 24 | $57.7M | $2.5M | ||
| Q2 24 | $60.3M | $2.0M | ||
| Q1 24 | $67.2M | $3.6M |
| Q4 25 | $45.4M | $9.6M | ||
| Q3 25 | $48.8M | $11.3M | ||
| Q2 25 | $58.6M | $7.0M | ||
| Q1 25 | $70.9M | $2.9M | ||
| Q4 24 | $82.9M | $2.5M | ||
| Q3 24 | $49.4M | $3.7M | ||
| Q2 24 | $52.4M | $3.1M | ||
| Q1 24 | $60.9M | $4.6M |
| Q4 25 | $61.9M | $12.8M | ||
| Q3 25 | $63.8M | $14.6M | ||
| Q2 25 | $75.7M | $10.4M | ||
| Q1 25 | $84.8M | $3.6M | ||
| Q4 24 | $97.2M | $3.3M | ||
| Q3 24 | $62.9M | $4.4M | ||
| Q2 24 | $66.1M | $4.0M | ||
| Q1 24 | $74.0M | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -398.3% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $-1.7M | ||
| Q3 25 | $-10.8M | $-1.4M | ||
| Q2 25 | $-8.3M | $-1.1M | ||
| Q1 25 | $-12.8M | $-1.6M | ||
| Q4 24 | $-10.3M | $-1.2M | ||
| Q3 24 | $-10.5M | $-1.4M | ||
| Q2 24 | $-9.2M | $-1.6M | ||
| Q1 24 | $-7.7M | $-1.8M |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | $-10.9M | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | $-7.8M | $-1.8M |
| Q4 25 | — | -398.3% | ||
| Q3 25 | -9043.3% | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | — | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | -3814.6% | -441.2% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | 15.0% | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | 0.0% | 3.0% | ||
| Q3 24 | 0.0% | 5.8% | ||
| Q2 24 | 0.0% | 8.5% | ||
| Q1 24 | 39.0% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
